What is the 13F Pro Quality Score for CNTX?

13F Pro ranks Context Therapeutics Inc. (CNTX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CNTX's current score at https://13fpro.ai/research/CNTX (free sign-up required for the full ranking).

Which hedge funds own the most CNTX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CNTX include MPM BioImpact, Deep Track Capital,, Nextech Invest, Ltd.. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/CNTX as soon as new 13F filings post.

Where does 13F Pro source CNTX data?

All Context Therapeutics Inc. fundamentals and ownership data come directly from SEC EDGAR. Context Therapeutics Inc. files with the SEC under CIK 1842952. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CNTX in?

Context Therapeutics Inc. (CNTX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CNTX research updated on 13F Pro?

CNTX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Context Therapeutics Inc.(CNTX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1842952 CNTX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

CNTX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Context Therapeutics Inc. (CNTX), a Healthcare sector company. CNTX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Context Therapeutics Inc. reports net income of $-8.7M, free cash flow of $-11.5M. Top institutional holders of CNTX by reported 13-F value include MPM BioImpact, Deep Track Capital,, Nextech Invest, Ltd., based on the most recent SEC filings. CNTX trades on the Nasdaq exchange and files with the SEC under CIK 1842952. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CNTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Context Therapeutics Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-8.7M

Free Cash Flow

Q1 2026

$-11.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-50.7% YoY

$-36.1MFY 2025

FY21 $-10.5MFY22 $-14.8MFY23 $-24.0MFY25 $-36.1M

Operating Income

-58.4% YoY

$-39.7MFY 2025

FY21 $-10.5MFY22 $-15.4MFY23 $-25.1MFY25 $-39.7M

EPS (Diluted)

+74.7% YoY

$-0.38FY 2025

FY21 $-3.69FY22 $-0.93FY23 $-1.50FY25 $-0.38

Total Assets

+326.4% YoY

$68.5MFY 2025

FY21 $51.3MFY22 $38.0MFY23 $16.1MFY25 $68.5M

Op. Cash Flow

-25.4% YoY

$-26.4MFY 2025

FY21 $-8.8MFY22 $-13.5MFY23 $-21.0MFY25 $-26.4M

Metric	FY 2025	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Net Income	$-36.1M -50.7%	$-24.0M -61.5%	$-14.8M -41.9%	$-10.5M -257.4%	$6.6M	—
Operating Income	$-39.7M -58.4%	$-25.1M -63.0%	$-15.4M -46.1%	$-10.5M -309.2%	$-2.6M	—
EPS (Diluted)	$-0.38 +74.7%	$-1.50 -61.3%	$-0.93 +74.8%	$-3.69 +6.8%	$-3.96	—
Total Assets	$68.5M +326.4%	$16.1M -57.7%	$38.0M -26.0%	$51.3M +10878.2%	$467.3K	—
Operating Cash Flow	$-26.4M -25.4%	$-21.0M -55.3%	$-13.5M -54.0%	$-8.8M -750.5%	$-1.0M	—

AI Insight: CNTX Financial Trends

CNTX equity eroded 49% in six quarters as operating cash burn accelerates with no revenue in sight.

• Equity declined from $101M in Q2 2024 to $52M in Q1 2026, a 49% reduction over six quarters.

• Operating cash outflow worsened from -$3M in Q2 2024 to -$11M in Q1 2026, nearly quadrupling.

• Operating losses widened from -$3M in Q2 2024 to -$14M in Q4 2025 before a slight improvement to -$9M in Q1 2026.

⚠ Zero revenue across all eight quarters; runway shrinks as equity falls toward $52M with accelerating cash burn.

⚠ Q3 2024 net loss spike to -$17M warrants scrutiny for one-time charges that could recur.

AI Insight: CNTX Ratio Trends

CNTX shows deeply negative and worsening capital returns across all metrics, with ROIC deteriorating from -12.2% in Q2 2024 to -91.3% in Q4 2025.

• ROIC deteriorated sharply from -12.2% in Q2 2024 to -91.3% in Q4 2025, reflecting accelerating capital destruction.

• ROA worsened from -8.8% in Q2 2024 to -76.1% in Q4 2025, signaling increasingly inefficient asset utilization.

• Q1 2026 shows partial improvement: ROIC recovered to -71.6% and ROA to -59.0% from Q4 2025 lows.

⚠ Q4 2025 ROIC hit -91.3% — the worst quarter on record — monitor whether Q1 2026 recovery sustains.

⚠ OpMargin, NPM, and D/E are entirely absent; cash burn trajectory cannot be fully assessed without these.

Get alerted when CNTX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Context Therapeutics Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CNTX

MPM BioImpact LLC
$28.0M10,679,391 sh
Deep Track Capital, LP
$19.4M7,419,355 sh
Nextech Invest, Ltd.
$19.4M7,419,355 sh
Soleus Capital Management, L.P.
$18.2M6,963,141 sh
Octagon Capital Advisors LP
$13.8M5,250,000 sh
Blue Owl Capital Holdings LP
$13.3M5,089,015 sh
Avidity Partners Management LP
$11.8M4,998,267 sh
FRANKLIN RESOURCES INC
$10.0M3,803,338 sh
VANGUARD CAPITAL MANAGEMENT LLC
$9.0M3,431,953 sh
MARSHALL WACE, LLP
$7.7M2,948,441 sh

Fund	Value	Shares
MPM BioImpact LLC	$28.0M	10,679,391
Deep Track Capital, LP	$19.4M	7,419,355
Nextech Invest, Ltd.	$19.4M	7,419,355
Soleus Capital Management, L.P.	$18.2M	6,963,141
Octagon Capital Advisors LP	$13.8M	5,250,000
Blue Owl Capital Holdings LP	$13.3M	5,089,015
Avidity Partners Management LP	$11.8M	4,998,267
FRANKLIN RESOURCES INC	$10.0M	3,803,338
VANGUARD CAPITAL MANAGEMENT LLC	$9.0M	3,431,953
MARSHALL WACE, LLP	$7.7M	2,948,441

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CNTX on your watchlist

Track score changes the day Context Therapeutics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CNTX a good stock to buy?

13F Pro's AI-powered analysis of Context Therapeutics Inc. (CNTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CNTX are available on the CNTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CNTX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CNTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Context Therapeutics Inc.'s investment landscape.